Table 10Prevalence of BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Populations

Author, yearPopulationWomen tested, NBRCA1 positive, nBRCA2 positive, nBRCA1 or BRCA2 positive, nBRCA1 mutation frequencyBRCA2 mutation frequencyBRCA1 or BRCA2 mutation frequency
Fodor et al, 1998209Population based (U.S.)17152018381.2%1.0%2.2%
Hartge et al, 1999214
Struewing et al, 199719
Population based (U.S.)37424841891.3%1.1%2.4%
Metcalfe et al, 2010191Population based (Canada)20801012220.5%0.6%1.1%
Oddoux et al, 1996224Population based (U.S.)1255120.9%
Roa et al, 199620Population based (U.S.)2717351.3%
Roa et al, 199620Population based (U.S.)2687371.4%
Roa et al, 199620Population based (Israel)40330.7%
Roa et al, 199620Population based (Israel)398102.5%
Struewing et al, 1995229Population based (U.S.)32730.9%
Struewing et al, 1995229Population based (Israel)36930.8%

From: 3, RESULTS

Cover of Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet].
Evidence Syntheses, No. 101.
Nelson HD, Fu R, Goddard K, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.